Bio-IT World December 23, 2024
AQEMIA intends to teach its generative AI platform quantum-inspired, atomic-scale physics to transform drug discovery; DeepLife plans to develop AI-powered models of human cells, known as digital twins of cells, for drug discovery; and more.
$161M: Series B for Autoimmune Dysregulation
Nuvig Therapeutics closed a $161 million Series B financing. Nuvig aims to deliver novel methods for reducing autoimmune dysregulation without immunosuppression. Lead candidate NVG-2089, a first-in-class, recombinant, Fc fragment immunomodulator, is engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that improves autoimmune dysregulation. The proceeds from the Series B financing will support clinical proof-of-concept studies for NVG-2089 and advance Nuvig’s preclinical pipeline. The company is progressing NVG-2089 to Phase...
Today's Sponsors
Today's Sponsor